Thermo Fisher Scientific Inc. $TMO Stock Position Lifted by Southpoint Capital Advisors LP

Southpoint Capital Advisors LP lifted its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 300.0% during the 1st quarter, Holdings Channel.com reports. The institutional investor owned 400,000 shares of the medical research company’s stock after buying an additional 300,000 shares during the period. Thermo Fisher Scientific comprises about 4.0% of Southpoint Capital Advisors LP’s holdings, making the stock its 9th largest position. Southpoint Capital Advisors LP’s holdings in Thermo Fisher Scientific were worth $196,612,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. Howard Capital Management Inc. grew its holdings in shares of Thermo Fisher Scientific by 0.5% during the 4th quarter. Howard Capital Management Inc. now owns 3,091 shares of the medical research company’s stock worth $1,791,000 after acquiring an additional 16 shares during the period. Salomon & Ludwin LLC boosted its position in shares of Thermo Fisher Scientific by 1.6% during the fourth quarter. Salomon & Ludwin LLC now owns 1,095 shares of the medical research company’s stock valued at $669,000 after purchasing an additional 17 shares in the last quarter. Pallas Capital Advisors LLC grew its stake in Thermo Fisher Scientific by 1.5% in the fourth quarter. Pallas Capital Advisors LLC now owns 1,256 shares of the medical research company’s stock worth $728,000 after purchasing an additional 18 shares during the period. Red Door Wealth Management LLC raised its holdings in Thermo Fisher Scientific by 0.8% in the fourth quarter. Red Door Wealth Management LLC now owns 2,156 shares of the medical research company’s stock worth $1,250,000 after purchasing an additional 18 shares in the last quarter. Finally, Elwood & Goetz Wealth Advisory Group LLC lifted its position in Thermo Fisher Scientific by 1.8% during the fourth quarter. Elwood & Goetz Wealth Advisory Group LLC now owns 1,031 shares of the medical research company’s stock valued at $597,000 after buying an additional 18 shares during the period. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research analysts recently issued reports on TMO shares. Piper Sandler increased their price target on shares of Thermo Fisher Scientific from $510.00 to $600.00 and gave the stock a “neutral” rating in a research note on Monday. Royal Bank Of Canada boosted their price objective on shares of Thermo Fisher Scientific from $490.00 to $580.00 and gave the stock a “sector perform” rating in a research note on Friday. Morgan Stanley lifted their target price on shares of Thermo Fisher Scientific from $620.00 to $650.00 and gave the company an “overweight” rating in a report on Friday. Jefferies Financial Group reaffirmed a “buy” rating and set a $630.00 price objective on shares of Thermo Fisher Scientific in a research report on Thursday. Finally, Sanford C. Bernstein began coverage on Thermo Fisher Scientific in a research note on Friday, June 26th. They issued a “market perform” rating and a $520.00 target price on the stock. One analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $617.14.

Thermo Fisher Scientific Price Performance

Shares of TMO opened at $558.79 on Tuesday. The firm has a fifty day simple moving average of $496.34 and a two-hundred day simple moving average of $512.33. The firm has a market cap of $207.66 billion, a PE ratio of 30.06, a P/E/G ratio of 2.51 and a beta of 0.87. The company has a current ratio of 1.55, a quick ratio of 1.18 and a debt-to-equity ratio of 0.74. Thermo Fisher Scientific Inc. has a 1-year low of $435.27 and a 1-year high of $643.99.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.71 by $0.32. The firm had revenue of $11.99 billion for the quarter, compared to the consensus estimate of $11.71 billion. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.The company’s revenue for the quarter was up 10.5% on a year-over-year basis. During the same period last year, the business posted $4.28 EPS. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. On average, equities analysts anticipate that Thermo Fisher Scientific Inc. will post 25.07 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Stockholders of record on Tuesday, September 15th will be given a dividend of $0.47 per share. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $1.88 annualized dividend and a dividend yield of 0.3%. Thermo Fisher Scientific’s dividend payout ratio is presently 10.11%.

About Thermo Fisher Scientific

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.